Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline ( (GB:GSK) ) has issued an update.
GlaxoSmithKline (GSK) has announced the purchase of 504,016 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on August 6, 2025, is part of a non-discretionary agreement with the broker and contributes to the company’s strategy of managing its capital structure. The shares will be held as treasury shares, and following this purchase, GSK holds 239,042,561 ordinary shares in treasury, with a total of 4,076,345,924 ordinary shares in issue. This move is significant for shareholders as it impacts the voting rights and shareholding calculations under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects strong financial performance and strategic initiatives, such as share buybacks and acquisitions, which enhance shareholder value. The technical indicators suggest a neutral market sentiment, while the valuation is fair with an attractive dividend yield. The earnings call highlights growth in specialty medicines, though challenges in vaccine sales and regulatory impacts are noted.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
Average Trading Volume: 9,063,325
Technical Sentiment Signal: Hold
Current Market Cap: £56.36B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.